vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-686Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSЭффективность применения повторных курсов лечения ритуксимабом у пациентки с тяжелым рефрактерным системным вариантом ювенильного ревматоидного артритаEFFICACY OF RECURRENT RITUXIMAB TREATMENT IN PATIENT WITH SEVERE REFRACTORY SYSTEMIC JUVENILE RHEUMATOID ARTHRITISАлексееваЕ.И.AlexeevaE.I.neonatepearl@yandex.ruДенисоваР.В.DenisovaR.V.neonatepearl@yandex.ruМоревС.Ю.MorevS.Yu.neonatepearl@yandex.ruМалаховО.О.MalakhovО.О.neonatepearl@yandex.ruМалаховО.А.MalakhovО.А.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, Москва
Первый Московский государственный медицинский университет им. И.М. СеченоваScientific Center of Children’s Health RAMS, Moscow
Sechenov First Moscow State Medical UniversityНаучный центр здоровья детей РАМН, МоскваScientific Center of Children’s Health RAMS, Moscow201116092011105Вопросы современной педиатрии157–163Copyright © Алексеева Е., Денисова Р., Морев С., Малахов О., Малахов О., 20112011Алексеева Е., Денисова Р., Морев С., Малахов О., Малахов О.Alexeeva E., Denisova R., Morev S., Malakhov О., Malakhov О.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/686ReferencesАлексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения: Руководство для врачей, преподавателей, научных сотрудников. Под ред. А. А. Баранова. М. 2007. С. 325–339.Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения: Руководство для врачей, преподавателей, научных сотрудников. Под ред. А. А. Баранова. М. 2007. С. 325–339.Бзарова Т.М., Алексеева Е.И., Петеркова В.А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Бзарова Т.М., Алексеева Е.И., Петеркова В.А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.Noorchashm H., Noorchashm N., Kern J. et al. B–cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997; 46: 941–946.Noorchashm H., Noorchashm N., Kern J. et al. B–cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997; 46: 941–946.Chan O.T., Hannum L.G., Haberman A.M. et al. A novel mouse with B–cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. J. Exp. Med. 1999; 189: 1639–1648.Chan O.T., Hannum L.G., Haberman A.M. et al. A novel mouse with B–cells but lacking serum antibody reveals an antibody independent role for B cells in murine lupus. J. Exp. Med. 1999; 189: 1639–1648.Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001; 167: 1072–1080.Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001; 167: 1072–1080.O’Neill S.K., Shlomchik M.J., Glant T.T. et al. Antigenspecific B cells are required as APCs and autoantibody producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005; 174: 3781–3788.O’Neill S.K., Shlomchik M.J., Glant T.T. et al. Antigenspecific B cells are required as APCs and autoantibody producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005; 174: 3781–3788.Anolik J. H., Barnard J., Cappione A. et al. Rituximab improves peripheral B–cell abnormalities in human systemic lupus erythematosus. Arthritis. Rheum. 2004; 50: 3580–3590.Anolik J. H., Barnard J., Cappione A. et al. Rituximab improves peripheral B–cell abnormalities in human systemic lupus erythematosus. Arthritis. Rheum. 2004; 50: 3580–3590.Wallace C.A., Sherry D.D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J. Rheumatol. 1992; 19: 1604–1607.Wallace C.A., Sherry D.D. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J. Rheumatol. 1992; 19: 1604–1607.Reiff A., Shaham B., Wood B. P. et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13: 113–118.Reiff A., Shaham B., Wood B. P. et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 1995; 13: 113–118.Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm. Res. 1996; 45: 91–95.Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm. Res. 1996; 45: 91–95.Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin. Rheumatol. 1998; 17: 505–510.Flato B., Vinje O., Forre O. Toxicity of antirheumatic and anti-inflammatory drugs in children. Clin. Rheumatol. 1998; 17: 505–510.Smolen E. C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 143–150.Smolen E. C., Emery P. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 143–150.Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011; 70 (9): 1575–1580.Chatzidionysiou K., Lie E., Nasonov E. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011; 70 (9): 1575–1580.Edwards J. C., Szczepanski L., Szechinski J. et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004; 350: 2572–2581.Edwards J. C., Szczepanski L., Szechinski J. et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004; 350: 2572–2581.Emery P., Fleischmann R., Filipowicz–Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double blind, placebo controlled, dose-ranging trial. Arthritis. Rheum. 2006; 54: 1390–1400.Emery P., Fleischmann R., Filipowicz–Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double blind, placebo controlled, dose-ranging trial. Arthritis. Rheum. 2006; 54: 1390–1400.Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty–four weeks. Arthritis. Rheum. 2006; 54: 2793–2806.Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty–four weeks. Arthritis. Rheum. 2006; 54: 2793–2806.Van Vollenhoven R.F., Emery P., Bingham C. O. et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 2010; 37: 558–567.Van Vollenhoven R.F., Emery P., Bingham C. O. et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 2010; 37: 558–567.Rubbert–Roth A., Tak P.P., Zerbini C. et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010; 49: 1683–1693.Rubbert–Roth A., Tak P.P., Zerbini C. et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010; 49: 1683–1693.Emery P., Deodhar A., Rigby W. F. et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexateEmery P., Deodhar A., Rigby W. F. et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate(SERENE). Ann. Rheum. Dis. 2010; 69: 1629–1635.(SERENE). Ann. Rheum. Dis. 2010; 69: 1629–1635.Tak P.P., Rigby W.F., Rubbert–Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 2011; 70: 39–46.Tak P.P., Rigby W.F., Rubbert–Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 2011; 70: 39–46.Loveless J. E., Olech E., Pritchard C. et al. An open label, prospective study of the safety of rituximab in combination with disease modifying anti–rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL). Arthritis. Rheum. 2009; 60: 1660.Loveless J. E., Olech E., Pritchard C. et al. An open label, prospective study of the safety of rituximab in combination with disease modifying anti–rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL). Arthritis. Rheum. 2009; 60: 1660.Kuek A., Hazleman B. L., Gaston J. H. et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford). 2006; 45: 1448–1449.Kuek A., Hazleman B. L., Gaston J. H. et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford). 2006; 45: 1448–1449.Foeldvari I., Bica B., Dedeoglu F. Efficacy of rituximab in RF factor negative juvenile idiopathic arthritis [FRI0450]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 502.Foeldvari I., Bica B., Dedeoglu F. Efficacy of rituximab in RF factor negative juvenile idiopathic arthritis [FRI0450]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 502.Алексеева Е.И., Валиева С.И., Бзарова Т.М. и др. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2009; 8 (5): 19–30.Алексеева Е.И., Валиева С.И., Бзарова Т.М. и др. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2009; 8 (5): 19–30.Alexeeva E.I., Valieva S.I., Bzarova T.M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30: 1163–1172.Alexeeva E.I., Valieva S.I., Bzarova T.M. et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin. Rheumatol. 2011; 30: 1163–1172.Wallace C.A. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.Wallace C.A. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
The authors declare that there are no conflicts of interest present.